Ventyx Biosciences, Inc. (VTYX)
NASDAQ$1.41
Market Cap
$100.29M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
130 of 924
Rank in Industry
86 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
VTYX Insider Trading Activity
VTYX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $1,260,462 | 3 | 33 |
Sells | $128,257 | 6 | 67 |
Related Transactions
| Mohan Raju | CEO AND PRESIDENT | 2 | $959,889 | 1 | $23,299 | $936,590 |
| Gujrathi Sheila | director | 1 | $300,573 | 0 | $0 | $300,573 |
| Auster Martin | CHIEF FINANCIAL OFFICER | 0 | $0 | 1 | $7,592 | $-7,592 |
| Krueger Christopher W | CHIEF BUSINESS OFFICER | 0 | $0 | 1 | $8,921 | $-8,921 |
| Nuss John | CHIEF SCIENTIFIC OFFICER | 0 | $0 | 3 | $88,444 | $-88,444 |
About Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the …
Insider Activity of Ventyx Biosciences, Inc.
Over the last 12 months, insiders at Ventyx Biosciences, Inc. have bought $1.26M and sold $128,257 worth of Ventyx Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Ventyx Biosciences, Inc. have bought $20.63M and sold $53.33M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Mohan Raju (CEO AND PRESIDENT) — $959,889. Gujrathi Sheila (director) — $300,573.
The last purchase of 130,000 shares for transaction amount of $300,573 was made by Gujrathi Sheila (director) on 2024‑12‑23.
List of Insider Buy and Sell Transactions, Ventyx Biosciences, Inc.
| 2024-12-27 | Sale | Nuss John | CHIEF SCIENTIFIC OFFICER | 21,119 0.0296% | $2.36 | $49,841 | -24.79% | |
| 2024-12-23 | Gujrathi Sheila | director | 130,000 0.1782% | $2.31 | $300,573 | -21.49% | ||
| 2024-12-19 | Sale | Nuss John | CHIEF SCIENTIFIC OFFICER | 13,161 0.0181% | $2.26 | $29,682 | -18.42% | |
| 2024-11-25 | Mohan Raju | CEO AND PRESIDENT | 261,752 0.3544% | $2.01 | $524,944 | -1.94% | ||
| 2024-11-22 | Mohan Raju | CEO AND PRESIDENT | 238,248 0.3281% | $1.83 | $434,946 | +10.00% | ||
| 2024-04-02 | Sale | Mohan Raju | CEO AND PRESIDENT | 4,312 0.0075% | $5.40 | $23,299 | -56.30% | |
| 2024-04-02 | Sale | Krueger Christopher W | CHIEF BUSINESS OFFICER | 1,651 0.0029% | $5.40 | $8,921 | -56.30% | |
| 2024-04-02 | Sale | Nuss John | CHIEF SCIENTIFIC OFFICER | 1,651 0.0029% | $5.40 | $8,921 | -56.30% | |
| 2024-04-02 | Sale | Auster Martin | CHIEF FINANCIAL OFFICER | 1,405 0.0024% | $5.40 | $7,592 | -56.30% | |
| 2023-12-20 | Sale | Mohan Raju | CEO and President | 58,860 0.1014% | $2.12 | $124,660 | +18.03% | |
| 2023-12-20 | Sale | Krueger Christopher W | Chief Business Officer | 5,293 0.0091% | $2.12 | $11,210 | +18.03% | |
| 2023-12-20 | Sale | Nuss John | Chief Scientific Officer | 17,628 0.0304% | $2.12 | $37,334 | +18.03% | |
| 2023-10-09 | Sale | Subramaniam Somu | 49,152 0.0835% | $30.03 | $1.48M | -91.63% | ||
| 2023-10-09 | Sale | NSV Partners III LP | 10 percent owner | 49,152 0.0835% | $30.03 | $1.48M | -91.63% | |
| 2023-10-05 | Sale | Mohan Raju | Chief Executive Officer | 30,000 0.0476% | $29.11 | $873,231 | -91.46% | |
| 2023-10-03 | Sale | Krueger Christopher W | Chief Business Officer | 15,000 0.0245% | $29.98 | $449,699 | -91.57% | |
| 2023-10-03 | Sale | Nuss John | Chief Scientific Officer | 10,000 0.0163% | $29.99 | $299,933 | -91.57% | |
| 2023-09-18 | Sale | Subramaniam Somu | 56,665 0.0964% | $37.81 | $2.14M | -92.72% | ||
| 2023-09-18 | Sale | NSV Partners III LP | 10 percent owner | 56,665 0.0964% | $37.81 | $2.14M | -92.72% | |
| 2023-09-05 | Sale | Mohan Raju | Chief Executive Officer | 30,000 0.0515% | $32.61 | $978,343 | -90.83% |
Total: 113
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Mohan Raju | CEO AND PRESIDENT | 2175028 3.0578% | $3.07M | 2 | 14 | |
| Gujrathi Sheila | director | 130000 0.1828% | $183,300.00 | 1 | 1 | |
| Royston Aaron | 3997269 5.6197% | $5.64M | 1 | 0 | <0.0001% | |
| venBio Global Strategic Fund III, L.P. | 10 percent owner | 3997269 5.6197% | $5.64M | 1 | 0 | <0.0001% |
| Cormorant Asset Management, LP | 1410303 1.9827% | $1.99M | 1 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$4,786,289 | 136 | 5.55% | $95.3M | |
$22,597,521 | 91 | 4.59% | $104.68M | |
$47,282,828 | 47 | -17.38% | $96.94M | |
$7,147,964 | 34 | 24.78% | $96.35M | |
$36,079,815 | 31 | 43.23% | $103.59M |
VTYX Institutional Investors: Active Positions
| Increased Positions | 74 | +61.67% | 18M | +34.53% |
| Decreased Positions | 47 | -39.17% | 16M | -30.83% |
| New Positions | 29 | New | 4M | New |
| Sold Out Positions | 20 | Sold Out | 7M | Sold Out |
| Total Postitions | 147 | +22.5% | 54M | +3.7% |
VTYX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $7,113.00 | 6.34% | 4.5M | -409,675 | -8.34% | 2024-12-31 |
| Citadel Advisors Llc | $7,081.00 | 6.31% | 4.48M | +26,457 | +0.59% | 2024-12-31 |
| Bank Of America Corp /De/ | $6,752.00 | 6.02% | 4.27M | +3M | +376.42% | 2024-12-31 |
| Sio Capital Management, Llc | $6,394.00 | 5.7% | 4.05M | +2M | +105.22% | 2024-12-31 |
| Ubs Group Ag | $5,976.00 | 5.33% | 3.78M | +3M | +215.9% | 2024-12-31 |
| Vanguard Group Inc | $5,543.00 | 4.94% | 3.51M | +40,366 | +1.16% | 2024-12-31 |
| Tang Capital Management Llc | $4,898.00 | 4.37% | 3.1M | 0 | 0% | 2024-12-31 |
| Morgan Stanley | $3,967.00 | 3.54% | 2.51M | +2M | +654.75% | 2024-12-31 |
| Vestal Point Capital, Lp | $3,160.00 | 2.82% | 2M | +275,000 | +15.94% | 2024-12-31 |
| Point72 Asset Management, L.P. | $2,816.00 | 2.51% | 1.78M | +2M | New | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.